Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2013

View Archived Issues

Abbott, Janssen and Pharmacyclics collaborate on companion test for leukemia therapy

KineMed, Isis Pharmaceuticals and CHDI Foundation form biomarker collaboration

NIH-funded trial of Shigella vaccine candidates to commence

New ACC1 inhibitors disclosed by Bayer Intellectual Property

University of Colorado and Orphan Technologies expand collaboration

FDA grants priority review to Epigenomics' PMA for Epi proColon

Zeria announces the Japanese launch of agent for hypophosphatemia

BioMarin licenses factor VIII gene therapy program for hemophilia A

Novel MPGES-1 inhibitors show promising anti-inflammatory properties

Novo Nordisk plans launch of Tresiba in Japan

Novel PAF receptor antagonists demonstrate neuroprotective properties

Abbott Laboratories synthesizes novel GlyT-1 inhibitors

Daiichi Sankyo discloses new hypoglycemic agents

Novel MAb shows potency as plasma kallikrein inhibitor

Novel RORgamma modulators patented by Tempero Pharmaceuticals

Biota Scientific Management presents new antiviral agents

Meda to begin phase II flupirtine trial in fibromyalgia

Pentraxin-related protein PTX3 levels are associated with carotid plaque vulnerability

EMA confirms decision on VIVUS' MAA for obesity treatment

Trastuzumab emtansine obtains first approval

NINDS funds tumor cell proliferation research at The Scripps Research Institute

Novartis terminates OX-17 program agreement with Orexo

NR2 peptide plasma assay as a new diagnostic tool for acute cerebrovascular events

Taxol approved for new indication in Japan

Phase III trial of cilengitide in glioblastoma fails to meet primary endpoint

Ablynx and Spirogen form anticancer drug conjugate collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...